Amp Volatility Score
Catalyst Info & Data Links
TITLE: Belapectin (GR-MD-02) for NASH-Cirrhosis - Phase 3
ClinicalTrial.gov (NCT04365868): Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
WHAT IS THE NEXT CATALYST EVENT?
Update on Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function.
Updated by JM
GALT, Galectin Therapeutics, Belapectin (GR-MD-02), NASH-cirrhosis
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post